ERASCA INC (ERAS)
Health Care · biotechnology · NASDAQ
Erasca is a precision oncology company dedicated to shutting down the RAS/MAPK pathway to effectively treat patients with cancer.
What ERASCA INC does
Erasca is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with cancer. The company utilizes a drug discovery engine to target biological drivers of cancer, specifically focusing on the RAS/MAPK pathway.
Themes: precision medicine, oncology, drug development
Fundamentals
- Price$15.46 as of 2026-10-08 close
- Market cap$5.4B as of 2026-08-04 (share count; price 2026-10-08)
- 1-year return+536.2% 2025-10-08 close $2.43 → 2026-10-08 close $15.46
- P/En/a negative earnings
- ROE-38.3% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Beta1.33 as of 2026-09-03
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How ERAS compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ERASCA INC looks technically
ERASCA INC (ERAS) is trading 10.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 255 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 20, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive). It made a new 20-day low about 12 trading days ago. It is 36.3% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 10.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +10.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $16.60 | $16.60 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $14.06 | $14.06 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 255 trading days ago — a "golden cross", a bullish long-term signal | 255 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 20, below the 25 that marks a real trend) | 19.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30) | 51.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($13.54 to $15.78) — its "stochastic" reading is 86 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 85.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $24.28 | $24.28 |
|---|---|---|
| From the 52-week high | it is 36.3% below its 52-week high (its highest price of the past year) | -36.3% |
| Above the 52-week low | it is 634.4% above its 52-week low (its lowest price of the past year) | +634.4% |
| Below the 52-week high | it is 36.3% below its highest point of the past year | 36.3% |
| Since a 20-day breakout | it made a new 20-day low about 12 trading days ago | 12 sessions |
| Since a 55-day breakout | it made a new 55-day low about 12 trading days ago | 12 sessions |
| All-time high | its highest closing price on record is $24.47 (set on 2021-09-07) | $24.47 |
| Given back of the 52-week move | over the past year its closes ranged ($2.20 to $22.47), and it has given back roughly a third of its rise from last year’s low — 35% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $9.29 to $9.94. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 34.6% |
| From the all-time high | it is 36.8% below its all-time high | -36.8% |
| Nearest price level | it is trading 9.8% below a resistance level at $16.98 — a price it turned at twice since 2026-08-03, most recently on 2026-08-24. Since 2024-10-08 it has 9 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +9.8% |
| All-time low | its lowest closing price on record is $1.01 (set on 2025-04-09) | $1.01 |
| Above the all-time low | it is 1430.7% above its all-time low | +1,431% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 77% of it) | 23rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.03 between its high and its low — about 6.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.03 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $13.54 and $16.26 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $13.54 – $14.90 – $16.26 |
| Typical daily range (% of price) | its price moves about 6.7% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.7% |
| Stretch from the 200-day average | it is trading 1.4 daily ranges above its 200-day average price (10.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.96× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.1% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.1% |
|---|---|---|
| Open gap | it gapped 2.8% below the previous close 59 sessions ago and has not traded back through the level it left behind at 21.26 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.8% |
| Gap filled | a 3.1% gap up opened on 2026-09-17 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 15 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 6.1 percentage points (the stock lost 5.0% while the market gained 1.0%) | -6.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 21.9 percentage points (the stock lost 18.1% while the market gained 3.8%) | -21.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 27.1 percentage points (the stock lost 9.7% while the market gained 17.5%) | -27.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 521.2 percentage points (the stock gained 536.2% while the market gained 15.0%) | +521.2% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: lagging the market over 6 months, near the top of its 14-day range (overbought), trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 12% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 6.1% of the share price. | -12.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 12% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $13.85 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +11.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% below the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is under water. That average is $16.05 — a volume-weighted average of daily closes over 42 sessions, not a true tick-by-tick VWAP. | -3.7% |
Price levels it has turned at before
ERAS last closed at $15.46 on 2026-10-08. Since 2024-10-08 it has turned at 9 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $16.98 | Resistance | 9.8% above the last close | turned there twice · 2026-08-03 to 2026-08-24 |
| $3.31 | Support | 78.6% below the last close | turned there three times · 2024-11-07 to 2025-12-23 |
| $2.83 | Support | 81.7% below the last close | turned there twice · 2025-01-07 to 2025-12-03 |
| $2.52 | Support | 83.7% below the last close | turned there twice · 2024-11-21 to 2025-10-30 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$24.11 range $20.00 – $33.00; median $22.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ERAS
- Consensus EPS estimate-$0.1302 next reporting period, as of 2026-10-08
- Estimate change, 30 days-$0.01846 from -$0.1117, on 2026-09-03, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company has a history of significant net losses and expects to continue to incur significant expenses as it advances its clinical programs.","The company is in the early stages of development and does not have any products approved for commercial sale, which creates uncertainty regarding its future revenue."]
What changed in the latest 10-Q
AI-assisted comparison of ERAS's 10-Q filed 2026-08-11 against the prior one filed 2026-05-11.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-11): Added heading 'ERAS-0015, our pan-RAS Molecular Glue' before the ERAS-0015 description.
- Newer filing (2026-08-11): Added statement that combination dose escalation cohorts included 'a panitumumab combination cohort'.
- Newer filing (2026-08-11): Added sentence 'In addition, we initiated a combination dose escalation cohort with pembrolizumab in the first quarter of 2026.'
- Removed:
- Older filing (2026-05-11): Removed paragraph 'The following figure shows the RAS/MAPK pathway and how the three therapeutic strategies listed above attempt to comprehensively and synergistically shut down the RAS/MAPK pathway.'
- Older filing (2026-05-11): Removed the 'including a pembrolizumab combination cohort' detail from the sentence about combination dose escalation cohorts.
- Reworded:
- Older filing (2026-05-11): Referred to 'combination dose escalation cohorts, including a pembrolizumab combination cohort', while newer filing (2026-08-11) changed this to 'combination dose escalation cohorts, including a panitumumab combination cohort'.
- Notes:
- Newer filing text appears truncated mid-sentence at 'Under the terms of the Tango CTCSA, we are providin', so changes after that point cannot be assessed.
- Older filing text appears truncated mid-sentence at 'Under the term', so changes after that point cannot be assessed.
- Comparison is limited to the provided excerpts; any changes outside these excerpts are not captured.
Risk Factors
- Added:
- New risk factor section added in the 2026-08-11 filing regarding securities class action litigation and a stockholder derivative complaint, including a purported securities class action complaint filed on June 10, 2026, and a purported stockholder derivative complaint filed in August 2026 in the United States District Court for the Southern District of California.
- Added in the 2026-08-11 filing: Underwriting Agreement dated July 13, 2026, by and among the Registrant and J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC and Evercore Group L.L.C., as exhibit 10.1 with 8-K filing date 7/14/2026.
- Removed:
- Removed in the 2026-08-11 filing: Underwriting Agreement dated January 21, 2026, by and among the Registrant and J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC and Evercore Group L.L.C., as exhibit 10.1 with 8-K filing date 1/22/2026.
- Reworded:
- In the Rule 10b5-1 Trading Plans disclosure, the quarter reference changed from "three months ended March 31, 2026" in the 2026-05-11 filing to "three months ended June 30, 2026" in the 2026-08-11 filing.
- Notes:
- The section includes more than the Risk Factors heading (Items 2-6, exhibits, signatures); comparison covers all content provided in both snippets.
- Page numbers differ between filings (e.g., 39, 40 in newer vs. 34, 35 in older); these are not treated as substantive changes.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-05. The 4 days since 2026-10-05 have not been checked yet.
Most recent open-market transaction: 2026-04-01. Based on Form 4 filings read through 2026-10-05; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ERAS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ERAS as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 39,015,918
- Reported value $714,771,621
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ERAS's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ERAS had 33,036,139 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ERAS had 9.45% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.65 days to cover at the same settlement.
- Reported short interest (shares) 33,036,139
- Short interest (% of shares outstanding) 9.45%
- Prior settlement (shares) 31,238,099
- Reported change 5.76%
- Days to cover (reported) 7.65
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Revolution Medicines (RVMD)
- Mirati Therapeutics (MRTX)
- SpringWorks Therapeutics (SWTX)
- BridgeBio Pharma (BBIO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ERAS vs…
ERASCA INC is found in…
ERAS ranks in…
Frequently asked questions
What does ERASCA INC (ERAS) do?
Erasca is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with cancer. The company utilizes a drug discovery engine to target biological drivers of cancer, specifically focusing on the RAS/MAPK pathway.
What sector is ERASCA INC (ERAS) in?
ERASCA INC (ERAS) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are ERASCA INC's (ERAS) competitors?
Notable peers of ERASCA INC (ERAS) include Revolution Medicines, Mirati Therapeutics, SpringWorks Therapeutics and BridgeBio Pharma. This peer set is informational only — not financial advice.
Is ERASCA INC (ERAS) overbought or oversold right now?
ERASCA INC (ERAS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 51, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ERAS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.